These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 26989206)

  • 61. Stem cell transplantation for mantle cell lymphoma: should it ever be used outside clinical trials?
    Sweetenham JW
    Bone Marrow Transplant; 2001 Nov; 28(9):813-20. PubMed ID: 11781640
    [TBL] [Abstract][Full Text] [Related]  

  • 62. High-dose therapy with autologous or allogeneic transplantation as salvage therapy for small cleaved cell lymphoma of follicular center cell origin.
    Stein RS; Greer JP; Goodman S; Kallianpur A; Ahmed MS; Wolff SN
    Bone Marrow Transplant; 1999 Feb; 23(3):227-33. PubMed ID: 10084253
    [TBL] [Abstract][Full Text] [Related]  

  • 63. High dose chemotherapy and autologous stem cell transplantation for poor risk and recurrent non-Hodgkin's lymphoma: a single-center experience of 50 patients.
    Shim BY; Lee MA; Byun JH; Roh SY; Song CW; Park JN; Lee JW; Min WS; Hong YS; Kim CC
    Korean J Intern Med; 2004 Jun; 19(2):114-20. PubMed ID: 15366643
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Relapsed/refractory pediatric B-cell non-Hodgkin lymphoma treated with rituximab combination therapy: A report from the Japanese Pediatric Leukemia/Lymphoma Study Group.
    Osumi T; Mori T; Fujita N; Saito AM; Nakazawa A; Tsurusawa M; Kobayashi R
    Pediatr Blood Cancer; 2016 Oct; 63(10):1794-9. PubMed ID: 27314926
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Allogeneic hematopoetic stem-cell transplantation for patients with relapsed or refractory lymphomas: comparison of high-dose conventional conditioning versus fludarabine-based reduced-intensity regimens.
    Bertz H; Illerhaus G; Veelken H; Finke J
    Ann Oncol; 2002 Jan; 13(1):135-9. PubMed ID: 11863095
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Autologous stem-cell transplantation for poor-risk and relapsed intermediate- and high-grade non-Hodgkin's lymphoma.
    Nademanee A; Molina A; Dagis A; Snyder DS; O'Donnell MR; Parker P; Stein A; Smith E; Planas I; Kashyap A; Spielberger R; Fung H; Krishnan A; Bhatia R; Wong KK; Somlo G; Margolin K; Chow W; Sniecinski I; Vora N; Slovak M; Niland JC; Forman SJ
    Clin Lymphoma; 2000 Jun; 1(1):46-54. PubMed ID: 11707813
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma.
    Epperla N; Ahn KW; Ahmed S; Jagasia M; DiGilio A; Devine SM; Jaglowski S; Kennedy V; Rezvani AR; Smith SM; Sureda A; Fenske TS; Kharfan-Dabaja MA; Armand P; Hamadani M
    J Hematol Oncol; 2017 Jun; 10(1):117. PubMed ID: 28606176
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Autologous and allogeneic hematopoietic stem cell transplantation in follicular lymphoma.
    Bhatt VR; Armitage JO
    Expert Opin Biol Ther; 2016; 16(1):57-66. PubMed ID: 26515478
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Rituximab reduces relapse risk after allogeneic and autologous stem cell transplantation in patients with high-risk aggressive non-Hodgkin's lymphoma.
    Shimoni A; Hardan I; Avigdor A; Yeshurun M; Raanani P; Ben-Bassat I; Nagler A
    Br J Haematol; 2003 Aug; 122(3):457-64. PubMed ID: 12877674
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Patterns of Failure and Survival Outcomes after Total Lymphoid Irradiation and High-Dose Chemotherapy with Autologous Stem Cell Transplantation for Relapsed or Refractory Classical Hodgkin Lymphoma.
    Paudel N; Schulze D; Gentzler RD; Evens AM; Helenowski I; Dillehay G; Frankfurt O; Mehta J; Donnelly ED; Gordon LI; Winter JN; Mittal BB
    Int J Radiat Oncol Biol Phys; 2019 Jun; 104(2):436-446. PubMed ID: 30763660
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Stem cell transplantation for lymphoma patients with HIV infection.
    Michieli M; Mazzucato M; Tirelli U; De Paoli P
    Cell Transplant; 2011; 20(3):351-70. PubMed ID: 20875226
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Intensive chemotherapy plus hematopoietic stem cells transplantation for relapsing non-Hodgkin's lymphoma: the GELA experience.
    Bosly A; Gisselbrecht C; Coiffier B
    Nouv Rev Fr Hematol (1978); 1993 Feb; 35(1):21-3. PubMed ID: 8099732
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Development of targeted therapies for B-cell non-Hodgkin lymphoma and multiple myeloma.
    Hernandez-Ilizaliturri FJ; Gowda A; Czuczman MS
    Clin Adv Hematol Oncol; 2004 Sep; 2(9):606-18. PubMed ID: 16163245
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network.
    Langner-Lemercier S; Houillier C; Soussain C; Ghesquières H; Chinot O; Taillandier L; Soubeyran P; Lamy T; Morschhauser F; Benouaich-Amiel A; Ahle G; Moles-Moreau MP; Moluçon-Chabrot C; Bourquard P; Damaj G; Jardin F; Larrieu D; Gyan E; Gressin R; Jaccard A; Choquet S; Brion A; Casasnovas O; Colin P; Reman O; Tempescul A; Marolleau JP; Fabbro M; Naudet F; Hoang-Xuan K; Houot R
    Neuro Oncol; 2016 Sep; 18(9):1297-303. PubMed ID: 26951382
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Hematopoietic stem cell transplantation in the new millennium: report from City of Hope National Medical Center.
    Molina A; Popplewell L; Kashyap A; Nademanee A
    Clin Transpl; 2000; ():317-42. PubMed ID: 11512326
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials Network.
    Laport GG; Wu J; Logan B; Bachanova V; Hosing C; Fenske T; Longo W; Devine SM; Nademanee A; Gersten I; Horowitz M; Lazarus HM; Riches ML;
    Biol Blood Marrow Transplant; 2016 Aug; 22(8):1440-1448. PubMed ID: 27118571
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Incidence of second cancers after allogeneic hematopoietic stem cell transplantation using reduced-dose radiation.
    Hsieh MM; Fitzhugh CD; Tisdale JF
    Blood; 2009 Jul; 114(1):225; author reply 225-6. PubMed ID: 19574484
    [No Abstract]   [Full Text] [Related]  

  • 79. Malignancies after hematopoietic stem cell transplantation: many questions, some answers.
    Deeg HJ; Socie G
    Blood; 1998 Mar; 91(6):1833-44. PubMed ID: 9490664
    [No Abstract]   [Full Text] [Related]  

  • 80. Autologous stem cell transplant in first remission for transformed indolent non-Hodgkin lymphoma: additional data to guide practice.
    Reneau JC; William BM
    Br J Haematol; 2020 Dec; 191(5):663-665. PubMed ID: 33065776
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.